Vicapsys Life Sciences, Inc. (VICP)
USD 1.77
(39.37%)
USD 1.77
(39.37%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 39.65 Thousand USD | -44.94% |
| 2022 | 72.02 Thousand USD | -87.88% |
| 2021 | 594.31 Thousand USD | 47.06% |
| 2020 | 404.11 Thousand USD | -42.14% |
| 2019 | 698.43 Thousand USD | -12.29% |
| 2018 | 796.33 Thousand USD | -26.05% |
| 2017 | 1.07 Million USD | 0.0% |
| 2009 | 2.23 Million USD | 108.65% |
| 2008 | 1.06 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q4 | 39.65 Thousand USD | -80.98% |
| 2023 Q2 | 378.14 Thousand USD | 497.45% |
| 2023 Q1 | 63.29 Thousand USD | -12.12% |
| 2023 Q3 | 208.48 Thousand USD | -44.87% |
| 2022 Q4 | 72.02 Thousand USD | -81.23% |
| 2022 Q3 | 383.8 Thousand USD | 0.42% |
| 2022 Q1 | 478.19 Thousand USD | -19.54% |
| 2022 Q2 | 382.2 Thousand USD | -20.07% |
| 2022 FY | 72.02 Thousand USD | -87.88% |
| 2021 Q4 | 594.31 Thousand USD | 7.63% |
| 2021 FY | 594.31 Thousand USD | 47.06% |
| 2021 Q3 | 552.17 Thousand USD | -1.82% |
| 2021 Q2 | 562.4 Thousand USD | 31.28% |
| 2021 Q1 | 428.4 Thousand USD | 6.01% |
| 2020 Q3 | 414.28 Thousand USD | -3.07% |
| 2020 Q4 | 404.11 Thousand USD | -2.45% |
| 2020 Q2 | 427.41 Thousand USD | -7.29% |
| 2020 Q1 | 461.04 Thousand USD | -33.99% |
| 2020 FY | 404.11 Thousand USD | -42.14% |
| 2019 Q3 | 950.27 Thousand USD | 0.0% |
| 2019 FY | 698.43 Thousand USD | -12.29% |
| 2019 Q4 | 698.43 Thousand USD | -26.5% |
| 2019 Q1 | - USD | -100.0% |
| 2018 Q4 | 796.33 Thousand USD | 0.0% |
| 2018 FY | 796.33 Thousand USD | -26.05% |
| 2017 FY | 1.07 Million USD | 0.0% |
| 2010 Q2 | 9.19 Million USD | 717.55% |
| 2010 Q1 | 1.12 Million USD | 50343.46% |
| 2009 Q4 | 2230.75 USD | 0.0% |
| 2009 FY | 2.23 Million USD | 108.65% |
| 2008 FY | 1.06 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | 86.743% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | 99.309% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 99.73% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 99.873% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | 98.768% |
| Better Therapeutics, Inc. | 22.94 Million USD | 99.827% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 99.862% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | 98.936% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 99.807% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 99.812% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 99.938% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | 98.315% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 99.944% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 99.848% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | 47.816% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | 99.674% |
| Molecular Templates, Inc. | 35.38 Million USD | 99.888% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | 99.093% |
| NexImmune, Inc. | 8.59 Million USD | 99.539% |
| Orgenesis Inc. | 14.55 Million USD | 99.727% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | 99.664% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | 68.184% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | 99.302% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | 89.891% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 99.992% |
| Statera Biopharma, Inc. | 21.16 Million USD | 99.813% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | 99.608% |
| Trevena, Inc. | 40.6 Million USD | 99.902% |
| Vaxxinity, Inc. | 44.35 Million USD | 99.911% |
| Vaccinex, Inc. | 3.63 Million USD | 98.908% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 99.93% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | 92.864% |